- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03770039
Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects
5 mars 2019 mis à jour par: Pfizer
A PHASE 1, OPEN-LABEL, NON-RANDOMIZED, 2-PERIOD, FIXED SEQUENCE STUDY TO INVESTIGATE THE ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION OF [14C-PF-06700841] AND TO ASSESS THE ABSOLUTE BIOAVAILABILITY AND FRACTION ABSORBED OF PF-06700841 IN HEALTHY MALE SUBJECTS USING A 14C-MICROTRACER APPROACH
An open-label, fixed sequence, 2-period including a single oral dose 60 mg PF-06700841 with 14C-labeled microtracer in 1st period, and a single oral dose of 60 mg unlabeled PF-06700841 followed by intravenous administration of 14C-labeled microdose of PF-06700841 1 hour after oral dose in period 2 to characterize the absorption, disposition, metabolism and excretion of PF-06700841 and evaluate the absolute bioavailability and fraction absorbed in the GI tract
Aperçu de l'étude
Statut
Complété
Les conditions
Type d'étude
Interventionnel
Inscription (Réel)
6
Phase
- La phase 1
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Groningen, Pays-Bas, 9728 NZ
- PRA Health Sciences
-
Utrecht, Pays-Bas, 3584 BL
- PRA Health Sciences Utrecht
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 55 ans (Adulte)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Homme
La description
Exclusion Criteria:
- Any clinically significant malabsorption condition (eg, gastrectomy, bowel resection).
- Total 14C radioactivity measured in plasma exceeding 11 mBq/mL
- History of tuberculosis or active or latent or inadequately treated infection, positive QuantiFERON®-TB Gold test
- Use of tobacoo/nicotine containing products 3-m prior to dosing or positive urine cotinine test
- Use of herbal supplements within 28 days prior to the first dose of study medication
- Use of prescription or nonprescription drugs (including vitamins and dietary supplements) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. As an exception, acetaminophen may be used at doses of 1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by Pfizer
- Inability to have at least one bowel movement every 2 days on average eGFR of <90 mL/mim/1.73 m2 based on MDRD equation
- Have been vaccinated with live or attenuated live vaccine within the 6 weeks prior to the first dose of investigational product, or expects to be vaccinated with these vaccines during study treatment, or within the 6 weeks following the last dose of investigational product.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Non randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: 2-period, fixed sequence
fixed sequence with 2 treatment period
|
Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period
60 mg unlabeled PF-06700841 oral dose in 2nd period
30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
mass balance_urine
Délai: hour 0 up to 312 hours post dose
|
cumulative recovery of radioactivity over time in urine, as percentage of total radioactive dose administered
|
hour 0 up to 312 hours post dose
|
mass balance_feces
Délai: hour 0 up to 312 hours post dose
|
cumulative recovery of radioactivity over time in feces, as percentage of total radioactive dose administered
|
hour 0 up to 312 hours post dose
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
metabolite identification_plasma
Délai: hour 0 up to 312 hours post dose
|
metabolic identification and profiling in plasma following a single oral dose of 14C-labeled PF-06700841
|
hour 0 up to 312 hours post dose
|
plasma Cmax for total 14C radioactivity
Délai: hour 0 up to 312 hours post dose
|
maximum concentration of total 14C radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841
|
hour 0 up to 312 hours post dose
|
plasma Tmax for total 14C radioactivity
Délai: hour 0 up to 312 hours post dose
|
time with highest concentration of radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841
|
hour 0 up to 312 hours post dose
|
plasma AUClast for total 14C radioactivity
Délai: hour 0 up to 312 hours post dose
|
area under curve of total 14C radioactivity in plasma from time 0 to tlast following a single oral dose of 14C-labeled PF-06700841
|
hour 0 up to 312 hours post dose
|
plasma AUCinf for total 14C radioactivity
Délai: hour 0 up to 312 hours post dose
|
area under curve of total 14C radioactivity in plasma from time 0 to infinite following a single oral dose of 14C-labeled PF-06700841
|
hour 0 up to 312 hours post dose
|
Oral clearance for total 14C radioactivity
Délai: hour 0 up to 312 hours post dose
|
oral clearance (CL/F) of total activity following a single oral dose of 14C-labeled PF-06700841
|
hour 0 up to 312 hours post dose
|
plasma half-life for total 14C radioactivity
Délai: hour 0 up to 312 hours post dose
|
half-life (t1/2) of total radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841
|
hour 0 up to 312 hours post dose
|
volume of distribution for total 14C radioactivity
Délai: hour 0 up to 312 hours post dose
|
apparent volume of distribution (Vz/F) of total radioactivity following a single oral dose of 14C-labeled PF-06700841
|
hour 0 up to 312 hours post dose
|
plasma Cmax for PF-06700841
Délai: hour 0 up to 96 hours post dose
|
maximum concentration of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841
|
hour 0 up to 96 hours post dose
|
plasma Tmax for PF-06700841
Délai: hour 0 up to 96 hours post dose
|
time with highest concentration of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841
|
hour 0 up to 96 hours post dose
|
plasma AUClast for PF-06700841
Délai: hour 0 up to 96 hours post dose
|
area under curve of PF-06700841 in plasma from time 0 to tlast following a single oral dose of 14C-labeled or unlabeled PF-06700841
|
hour 0 up to 96 hours post dose
|
plasma AUCinf for PF-06700841
Délai: hour 0 up to 96 hours post dose
|
area under curve of PF-06700841 in plasma from time 0 to infinite following a single oral dose of 14C-labeled or unlabeled PF-06700841
|
hour 0 up to 96 hours post dose
|
Oral clearance for PF-06700841
Délai: hour 0 up to 96 hours post dose
|
oral clearance (CL/F) of PF-06700841 following a single oral dose of 14C-labeled or unlabeled PF-06700841
|
hour 0 up to 96 hours post dose
|
plasma half-life for PF-06700841
Délai: hour 0 up to 96 hours post dose
|
half-life (t1/2) of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841
|
hour 0 up to 96 hours post dose
|
volume of distribution for PF-06700841
Délai: hour 0 up to 96 hours post dose
|
apparent volume of distribution (Vz/F) of PF-06700841 following a single oral dose of 14C-labeled or unlabeled PF-06700841
|
hour 0 up to 96 hours post dose
|
plasma Cmax for 14C-labeled PF-06700841
Délai: hour 0 up to 96 hours post dose
|
maximum concentration of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841
|
hour 0 up to 96 hours post dose
|
plasma Tmax for 14C-labeled PF-06700841
Délai: hour 0 up to 96 hours post dose
|
time with highest concentration of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841
|
hour 0 up to 96 hours post dose
|
plasma AUClast for 14C-labeled PF-06700841
Délai: hour 0 up to 96 hours post dose
|
area under curve of 14C-labeled PF-06700841 in plasma from time 0 to tlast following a single iv dose of 14C-labeled PF-06700841
|
hour 0 up to 96 hours post dose
|
plasma AUCinf for 14C-labeled PF-06700841
Délai: hour 0 up to 96 hours post dose
|
area under curve of 14C-PF-06700841 in plasma from time 0 to infinite following a single iv dose of 14C-labeled PF-06700841
|
hour 0 up to 96 hours post dose
|
clearance for 14C-labeled PF-06700841
Délai: hour 0 up to 96 hours post dose
|
clearance (CL) of 14C-labeled PF-06700841 following a single iv dose of 14C-labeled PF-06700841
|
hour 0 up to 96 hours post dose
|
plasma half-life for 14C-labeled PF-06700841
Délai: hour 0 up to 96 hours post dose
|
half-life (t1/2) of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841
|
hour 0 up to 96 hours post dose
|
volume of distribution for 14C-labeled PF-06700841
Délai: hour 0 up to 96 hours post dose
|
volume of distribution (Vz/F) of 14C-labeled PF-06700841 following a single iv dose of 14C-labeled PF-06700841
|
hour 0 up to 96 hours post dose
|
unchanged PF-06700841 recovered in urine
Délai: hour 0 up to 96 hours post dose
|
percentage of unchanged PF-06700841 recovered in urine (Ae%) following a single oral dose of PF-06700841
|
hour 0 up to 96 hours post dose
|
renal clearance of PF-06700841
Délai: hour 0 up to 96 hours post dose
|
renal clearance (CLr) following a single oral dose of PF-06700841 (Ae%/AUCinf for PF-06700841)
|
hour 0 up to 96 hours post dose
|
Bioavailability of oral PF-06700841
Délai: hour 0 up to 96 hours post dose
|
Absolute bioavailability (F) following a single oral dose relative to a single iv dose of PF-06700841
|
hour 0 up to 96 hours post dose
|
Fraction absorbed of oral PF-06700841
Délai: hour 0 up to 144 hours post dose
|
Fraction absorbed in gut (Fa) following oral dose of PF-06700841
|
hour 0 up to 144 hours post dose
|
metabolite identification_urine
Délai: hour 0 up to 312 hours post dose
|
metabolic identification and profiling in urine following a single oral dose of 14C-labeled PF-06700841
|
hour 0 up to 312 hours post dose
|
metabolite identification_feces
Délai: hour 0 up to 312 hours post dose
|
metabolic identification and profiling in feces following a single oral dose of 14C-labeled PF-06700841
|
hour 0 up to 312 hours post dose
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
10 décembre 2018
Achèvement primaire (Réel)
21 février 2019
Achèvement de l'étude (Réel)
21 février 2019
Dates d'inscription aux études
Première soumission
6 décembre 2018
Première soumission répondant aux critères de contrôle qualité
6 décembre 2018
Première publication (Réel)
10 décembre 2018
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
6 mars 2019
Dernière mise à jour soumise répondant aux critères de contrôle qualité
5 mars 2019
Dernière vérification
1 mars 2019
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- B7931014
- 2018-002403-34 (Numéro EudraCT)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Non
Description du régime IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Oui
Étudie un produit d'appareil réglementé par la FDA américaine
Non
produit fabriqué et exporté des États-Unis.
Oui
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Sujets masculins en bonne santé
-
AstraZenecaParexelComplété